Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Arima S, Kawahira M, Shimokawa M, Ido A, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Mitsugi K, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Otsuka T. Arima S, et al. Among authors: shimokawa m. Pancreas. 2021 Aug 1;50(7):957-964. doi: 10.1097/MPA.0000000000001859. Pancreas. 2021. PMID: 34347735
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y. Miyamoto Y, et al. Among authors: shimokawa m. Int J Clin Oncol. 2016 Aug;21(4):705-712. doi: 10.1007/s10147-015-0943-z. Epub 2016 Jan 8. Int J Clin Oncol. 2016. PMID: 26746689 Clinical Trial.
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Takahashi T, et al. Among authors: shimokawa m. Cancer Chemother Pharmacol. 2016 Sep;78(3):585-93. doi: 10.1007/s00280-016-3109-4. Epub 2016 Jul 28. Cancer Chemother Pharmacol. 2016. PMID: 27468920 Clinical Trial.
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer. Satake H, et al. Among authors: shimokawa m. Cancer Chemother Pharmacol. 2017 Jan;79(1):147-153. doi: 10.1007/s00280-016-3204-6. Epub 2016 Dec 10. Cancer Chemother Pharmacol. 2017. PMID: 27942930 Free PMC article. Clinical Trial.
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Ando K, et al. Among authors: shimokawa m. Int J Clin Oncol. 2017 Oct;22(5):913-920. doi: 10.1007/s10147-017-1140-z. Epub 2017 May 19. Int J Clin Oncol. 2017. PMID: 28526907 Clinical Trial.
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, Nagase M, Negoro Y, Tsuda T, Shimodaira H, Okano N, Tsuji A, Sakai D, Yanagihara K, Ueda S, Tamura S, Otsu S, Honda T, Matsushita Y, Okuno T, Kashiwada T, Nozaki A, Ebi M, Okuda H, Shimokawa M, Hironaka S, Hyodo I, Baba E, Boku N, Muro K, Esaki T. Makiyama A, et al. Among authors: shimokawa m. Gastric Cancer. 2018 Sep;21(5):792-801. doi: 10.1007/s10120-018-0797-y. Epub 2018 Jan 20. Gastric Cancer. 2018. PMID: 29353332 Clinical Trial.
Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Tanioka H, et al. Among authors: shimokawa m. Oncology. 2018;94(5):289-296. doi: 10.1159/000486624. Epub 2018 Mar 7. Oncology. 2018. PMID: 29514163 Clinical Trial.
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Saeki H, et al. Among authors: shimokawa m. Eur J Cancer. 2018 Dec;105:41-49. doi: 10.1016/j.ejca.2018.09.024. Epub 2018 Nov 2. Eur J Cancer. 2018. PMID: 30391779
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M. Suzuki N, et al. Among authors: shimokawa m. Int J Clin Oncol. 2019 Oct;24(10):1223-1230. doi: 10.1007/s10147-019-01473-3. Epub 2019 May 29. Int J Clin Oncol. 2019. PMID: 31144145 Free PMC article. Clinical Trial.
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M. Yuki S, et al. Among authors: shimokawa m. Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25. Cancer Chemother Pharmacol. 2020. PMID: 31768696 Clinical Trial.
436 results